EUVIMEDEUVIMED entdecken
Open Access

Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants

Alex Bataller iD, Sanam Loghavi iD, Yoheved Gerstein, Alexandre Bazinet iD, Koji Sasaki iD, Kelly S Chien iD, Danielle Hammond, Guillermo Montalban-Bravo iD, Gautam Borthakur iD, Nicholas Short iD, Ghayas C Issa iD, Tapan M Kadia iD und 12 weitere

American Journal of Hematology · 2023

DOI: 10.1002/ajh.27070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Alex Bataller und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: DEAD-box RNA Helicases, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Leukemia and Lymphoma Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DDX41 is the most frequently mutated gene in myeloid neoplasms associated with germline predisposition including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). We analyzed 3795 patients with myeloid neoplasms and identified 151 (4%) with DDX41 variants and a diagnosis of AML ( n = 96), MDS ( n = 52), and chronic myelomonocytic leukemia ( n = 3). The most frequent DDX41 variants were the somatic variant p.R525H, followed by the germline variants p.M1I and p.D140fs. Most neoplasms had a normal karyotype (59%) and the most frequent co‐mutations were TP53 (16%) and ASXL1 (15%). 30% of patients had no concomitant mutations besides DDX41 mutation. Patients with myeloid malignancies and DDX41 variants responded well to therapy, with an overall response rate for patients with treatment naïve AML and MDS of 87% and 84%, respectively. The median overall survival (mOS) of patients with treatment‐naïve AML or MDS was 49 and 71 months, respectively. Patients with AML treated with low‐intensity regimens including venetoclax had an improved survival (2‐year OS 91% vs. 60%, p = .02) and lower cumulative incidence of relapse compared to those treated without venetoclax (10% vs. 56%, p = .03). In the 33% of patients receiving hematopoietic stem cell transplantation, the 2‐year OS was 80% and 85% for AML and MDS, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DEAD-box RNA HelicasesMyelodysplastic SyndromesLeukemia, Myeloid, AcuteHumansMaleFemaleMiddle AgedAgedAdultAged, 80 and overSulfonamidesBridged Bicyclo Compounds, HeterocyclicMutationLeukemia, Myelomonocytic, ChronicTreatment OutcomeYoung AdultGerm-Line MutationTumor Suppressor Protein p53Repressor Proteins

Substanzen

DEAD-box RNA HelicasesDDX41 protein, humanvenetoclaxSulfonamidesBridged Bicyclo Compounds, HeterocyclicASXL1 protein, humanTumor Suppressor Protein p53Repressor Proteins

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Alex Bataller, Sanam Loghavi, Alexandre Bazinet, Koji Sasaki, Kelly S Chien, Guillermo Montalban-Bravo, Gautam Borthakur, Nicholas Short, Ghayas C Issa, Tapan M Kadia, Naval Daver, Guilin Tang, Farhad Ravandi, Hagop M Kantarjian, Kapil Bhalla, Guillermo Garcia-Manero, Courtney D DiNardo

Förderung

  • NCI NIH HHS
  • Leukemia and Lymphoma Society

Zitieren

APA

Bataller, A., Loghavi, S., Gerstein, Y., Bazinet, A., Sasaki, K., Chien, K. S., Hammond, D., Montalban-Bravo, G., Borthakur, G., Short, N., Issa, G. C., Kadia, T. M., Daver, N., Tang, G., Quesada, A., Patel, K. P., Ravandi, F., Fiskus, W., Mill, C. P., …, & DiNardo, C. D. (2023). Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. American Journal of Hematology. https://doi.org/10.1002/ajh.27070

Vancouver

Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, et al. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. American Journal of Hematology. 2023. doi:10.1002/ajh.27070

BibTeX
@article{Bataller2023,
  author = {Bataller, Alex and Loghavi, Sanam and Gerstein, Yoheved and Bazinet, Alexandre and Sasaki, Koji and Chien, Kelly S and Hammond, Danielle and Montalban-Bravo, Guillermo and Borthakur, Gautam and Short, Nicholas and Issa, Ghayas C and Kadia, Tapan M and Daver, Naval and Tang, Guilin and Quesada, Andres and Patel, Keyur P and Ravandi, Farhad and Fiskus, Warren and Mill, Cristopher P and Kantarjian, Hagop M and Bhalla, Kapil and Garcia-Manero, Guillermo and Oran, Betul and DiNardo, Courtney D},
  title = {Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.27070}
}
Kostenlos starten →